Synthego, a Bay Area biotech startup that won hundreds of millions of dollars in funding for its gene editing products and ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

The Beachwood-based company announced on Tuesday, May 20, that it has appointed Dr. David Llewellyn as its new CEO and as a ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...